I know you bought it at the very very bottom... and of course sold it all at the ultimate top... so now its a pos. I got to get a bucket of money.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
WHT
closer look
I am hoping it goes thru 4 but that is prolly a streach.
real
now its working... doh
TRPH LOW ZONE CHART will it go thru 4.... comments
I am missing all the fun. ;( ugh
real
did you try omni's kick start on the ibox
real
Stock Hippie... is that esignal that good... your da man!
real
TRPH fell threw resistance a good buy level
Prolly got his finger on the big button.
real
sfe on watch
going to guy GZFX a bottle of Cialas... cause it has trouble getting up
real
OT star trader and 4x and giving seminars by my house today...
real
that VWPT is wild
TRPH VION GOING OFF
VWPT GOING OFF
nite billy see ya later.
real
Yeah I'll give it a real college try before I hit you up whining with my results...or lack of. Once I get it working on a rudimentary level at least. Thanks... did you see post #75728 <LOL
real
shades of FTUS
real
OT March Madness... this board is dead...
real
hey Omni, Trying my hand at scanning.... my talents at this leave much to be desired. I keep getting no results...
real
I am on speed a learning course since I got here. Its all making so much more sense.
In fact there was a woman talking about the NADASQ on CNBC today and she was going on about the 200ma and such and I actually new what she was talking about. SCAAARY Dudes......
real
Heeeeeeeeeeeey BILLY!
GZFX.... he he he
I would love to hear all of it buys and sells.... mama needs a new puter and so do I. Then onward an upward to level 2 and realtime charts. yehaaa! LOL
real
Hey Omni, Whats your take on
GZFX..... he he he
The Tick adn Trin are cooked.
real
You bet dude with a double of Kaluah for the pain. You catch that MWAV or the MAHI? Me I am sitting here wittling a fishing rod waiting for Cheesy Effects (GZFX) to get all the playa's in place.
real
eeei eeeeei OOOOOOH
real
its volume is flat.... the market is draggin it down.... if it closes down its a stealty red candle ....cause sombody is buying it at .111
TBIO ALERT
News for 'TBIO' - (Transgenomic to Provide Manufacturing Support for
Development of Novel Regulatable Anticoagulant Drug Partnering with
Regado Biosciences to Advance Synthetic Nucleic Acid Drug-Antidote Pair
Toward Clinic)
OMAHA, Neb., Mar 22, 2004 /PRNewswire-FirstCall via COMTEX/ --
Transgenomic
Inc. (Nasdaq: TBIO) announced today that it has signed a contract with
North
Carolina-based Regado Biosciences to manufacture the two components of an
antidote-controlled, regulatable anticoagulant therapy. Transgenomic will
also
provide a range of related services, including analytical method
development,
stability studies and other related formulation development activities, in
support of Regado's advance toward an investigational new drug (IND)
filing.
Oligonucleotide manufacturing and related development work will be
completed at
the Company's facility in Boulder, Colo. Some of the chemical building
blocks
that serve as raw materials in synthetic DNA and/or RNA manufacture will
be
supplied by Transgenomic's plant in Glasgow, Scotland, for this and future
work.
Regado has developed antidote-controlled aptamer technology, allowing the
reversal of an aptamer's therapeutic activity. Regado's development-stage
anticoagulant therapy consists of an RNA-based aptamer, which inhibits the
therapeutic target, and a synthetic oligonucleotide, which binds the
aptamer and
functions as the "antidote." Appropriately timed use of the two molecules
in
combination represents a novel approach aimed at reducing potential
complications associated with antithrombotic therapies. This technology,
as
described in the journal Nature (Rusconi et al. 2002. Nature 419: 90-94),
has
been shown to reverse the anti-clotting activity of Regado's lead
anticoagulant
aptamer in both cellular and animal models.
"We are delighted to have the opportunity to partner with Regado in their
efforts to move their innovative regulatable drug-antidote technology
toward the
clinic," said Collin D'Silva, Transgenomic's CEO. "Regado is the type of
customer likely to reap maximum benefit from our position as a
vertically-integrated supplier of nucleic acids products and value-added
services. Our combined offerings provide a comprehensive solution to
support the
transition from research to production-scale cGMP manufacturing and enable
progression through the clinical development process."
Doug Gooding, CEO of Regado Biosciences, commented that Transgenomic's
synthetic
nucleic acid manufacturing and development expertise is a valuable asset
in
Regado's clinical development efforts. "Our RNA-based lead drug candidate
requires both the incorporation of non-standard nucleic acid building
blocks, as
well as other chemical modifications. We believe Transgenomic will prove
to be a
valued partner in this development process, as the company possesses a
significant proportion of what is currently a limited pool of experience
and
expertise in this area. Their activities on our behalf will allow us to
focus
our energies on our clinical trials strategy and continuing the evolution
of our
technology platform."
About Regado
Regado Biosciences is an early-stage biopharmaceutical company positioned
to
become a world leader in the discovery, development and commercialization
of
antidote-controlled therapeutics. Its proprietary technology allows Regado
to
generate highly specific antidotes for each new drug it develops. The
rational
design of drug-antidote pairs represents a new paradigm for developing
safer
therapeutics that address multi-billion dollar markets in acute care
medicine.
The initial focus of the Company is on developing antidote-controlled
drugs that
prevent or eliminate blood clots ("antithrombotics").
For more information, please contact Doug Gooding at 919-949-2990.
About Transgenomic
Transgenomic provides versatile and innovative research tools and related
consumable products to the life sciences industry for the synthesis,
separation,
analysis and purification of nucleic acids and a wide variety of nucleic
acid-based specialty chemicals. Transgenomic's BioSystems segment offers
its
WAVE(R) Systems and associated consumables. These systems are specifically
designed for use in genetic variation detection and single- and
double-strand
DNA/RNA analysis and purification. These systems have broad applicability
to
genetic research and molecular diagnostics. To date there have been over
one
thousand systems installed in over 30 countries around the world. In
addition,
the BioSystems segment offers WAVE-based biomarker discovery and
validation
services in support of translational research, pre-clinical and clinical
studies.
Through its nucleic acids business segment, Transgenomic provides
specialty
chemicals, including advanced nucleic acid building blocks and associated
reagents, used in applications such as genetic diagnostics and
therapeutics, as
well as a comprehensive menu of services, including nucleic acid chemistry
R&D,
process development, analytical methods development, cGMP oligonucleotide
manufacturing, quality control and regulatory support.
For more information about the innovative genomics research tools
developed and
marketed by Transgenomic, please visit the Company's Web site at
www.transgenomic.com.
Cautionary Statement
Certain statements in this press release constitute "forward-looking
statements"
of Transgenomic within the meaning of the Private Securities Litigation
Reform
Act of 1995, which involve known and unknown risks, uncertainties and
other
factors that may cause our actual results to be materially different from
any
future results, performance or achievements expressed or implied by such
statements. Forward-looking statements include, but are not limited to,
those
with respect to supporting the transition of drug candidates from research
to
production-scale cGMP manufacturing and enabling progression through the
clinical development process. The known risks, uncertainties and other
factors
affecting these forward-looking statements are described from time to time
in
Transgenomic's reports to the Securities and Exchange Commission. Any
change in
such factors, risks and uncertainties may cause the actual results, events
and
performance to differ materially from those referred to in such
statements.
Accordingly, the company claims the protection of the safe harbor for
forward-looking statements contained in the Private Securities Litigation
Reform
Act of 1995 with respect to all statements contained in this press
release. All
information in this press release is as of the date of the release and
Transgenomic does not undertake any duty to update this information,
including
any forward-looking statements, unless required by law.
For confirmation of release or further information contact:
Transgenomic:
Mitchell L. Murphy Robert J. Pogulis, Ph.D.
Transgenomic Inc. Transgenomic Inc.
402-452-5418 845-782-9617
mmurphy@transgenomic.com rpogulis@transgenomic.com
Regado Biosciences
Doug Gooding
Regado Biosciences
919-949-2990
SOURCE Transgenomic Inc.
CONTACT: Mitchell L. Murphy, +1-402-452-5418,
mmurphy@transgenomic.com,
or Robert J. Pogulis, Ph.D., +1-845-782-9617,
rpogulis@transgenomic.com, both
of Transgenomic Inc.; or Doug Gooding of Regado
Biosciences, +1-919-949-2990
URL: http://www.transgenomic.com
http://www.prnewswire.com
Copyright (C) 2004 PR Newswire. All rights reserved.
-0-
KEYWORD: Nebraska
North Carolina
Scotland
Colorado
INDUSTRY KEYWORD: HEA
MTC
BIO
SUBJECT CODE: PDT
CON
Source: Comtext Market News
Compliments of Scottrade.com
At least their noticing it
real
GXFX MAILCALL
News for 'GZFX' - (Financial Relations Inc: HotStockChat.com reports on
Stocks of Interest and Stocks on the Move on the OTCBB for March 22,
2004)
Virginia Beach, VA, Mar 22, 2004 (M2 PRESSWIRE via COMTEX) --
HotStockChat.com`s morning scans of moving stocks on the OTCBB and Pink
Sheets
revealed a short list of stocks on the move this morning. Volume is light
on the
OTCBB today.
Among Stocks of interest today, Cipher Holdings Corp. (OTCBB: CIHR) is now
moving up strongly for the third straight day. The stock has moved from
around
60 on Thursday of last week to a high of $2.00 so far today. At
HotStockChat.com, a Company Background Information profile is available at
http://www.hotstockchat.com/cihr.htm. GameZnFlix, Inc. (OTCBB: GZFX) is
moving
up a little again today. The stock is up .0049 to .112. Biotech Holdings
(TSX-VEN: BIO.V; OTCBB: BIOHF) continues to move up; the stock gapped this
morning to .65. The stock is trading at .635 up .075. Unity Wireless
Corporation
(OTCBB: UTYW; Germany: WKN#924385) is moving nicely for the third straight
day.
The stock is trading at .64, up .08 so far this morning.
Details regarding these stocks as well as other stocks of interest and
stocks on
the move can be found at http://www.hotstockchat.com by noon EST.
Today`s Statistics for the OTCBB as of 9:55AM EDT are as follows:
Advancing
Issues: 276 Declining Issues: 337 Unchanged Issues: 252 New Highs/New
Lows: 17/4
Total Volume: 87,533,056
About HotStockChat.com
HotStockChat.com is a media and information site dealing with the OTCBB,
Pink
Sheets, AMEX and NASDAQ stock markets. HotStockChat.com produces quality
and
timely audio content that is unique and offers market participants and
investors
a different look at the markets. Audio interviews are regularly conducted
with
company officials as well as individuals associated with the stock
markets.
Market statistics and updates on individual stocks of interest are
transmitted
to HotStockChat.com subscribers daily via email and are posted at the web
site
at http://www.hotstockchat.com by early afternoon each weekday.
HotStockChat.com also assists publicly traded companies by providing
consulting
services, Investor Relations Services and a variety of financing options
as well
as availability of public trading shells. HotStockChat.com also assists
privately owned companies with financing through reverse mergers.
HotStockChat.com specialized in Investor Relations Services for newly
merged
companies and companies that are ready to go public.
The above news release may contain forward-looking statements and/or
announcements. The list of stocks on HotStockChat.com`s "scans" and
"stocks of
interest" are for informational purposes only and should not be construed
as an
offer or solicitation of an offer to buy or sell securities of the
companies
listed in this news release or on the web site at
http://www.hotstockchat.com.
HotStockChat.com is a services and advertising company only.
HotStockChat.com is
not a licensed broker, broker dealer, market marker, investment banker,
investment advisor, analyst or underwriter. Please consult a broker before
purchasing any stock of any company listed in news releases, interviewed
and/or
profiled at http://www.hotstockchat.com. HotStockChat.com features
interviews
and profiles of publicly traded companies. In most cases we are
compensated for
the services rendered by a third party on behalf of the company.
HotStockChat.com generally has no position in any company mentioned in
this
daily news release. However, HotStockChat.com`s principles and associates
may
have bought or may buy the shares of stocks that we profile/interview or
list in
news releases and may profit in the event those shares rise in value. At
this
time, HotStockChat.com owns no position in any company mentioned in this
news
release. HotStockChat.com expects to receive $7,500 cash for the Company
Background Information profile and subsequent interview on behalf of
Cipher
Holding Corp. (OTCBB: CIHR) from CLX Associates, Inc. HotStockChat.com
received
no compensation from any third party or company to mention any of the
other
companies in this news release. HotStockChat.com regularly updates our
disclaimer page and will post how many shares sold of any given stock that
we
have profiled or interviewed. Additionally, HotStockChat.com will not
offer any
opinion as to when others should sell; each investor must make that
decision
based on their own due diligence of the company.
CONTACT: Tom Allinder, HotStockChat.com Tel: +1 757 721 6136 e-mail:
services@hotstockchat.com
M2 Communications Ltd disclaims all liability for information provided
within M2
PressWIRE. Data supplied by named party/parties. Further information on M2
PressWIRE can be obtained at http://www.presswire.net on the world wide
web.
Inquiries to info@m2.com.
(C)1994-2004 M2 COMMUNICATIONS LTD
-0-
Source: Comtex Wall Street News
Compliments of Scottrade.com
KNOS I wish GZFX could do this
for real
http://stockcharts.com/def/servlet/SharpChartv05.ServletDriver?chart=knos,uu[w,a]daclyyay[db][ph.02,...
Mahi is a sweet play congrats
long as it keeps painting happy little candles
real
GZFX So far we are painting a happy candle :) The Bob Ross happy little candle number system.
real
Is this what they call market correction 101
real
congrats to whoever is in MWAV
real
WHT creeping along... the turtle won the race
The market is going down like Moby dick ...Going down ... she is sounding..
real
It is one site... a dns pointer is just typing a name or many names and they all point to one site. Would be sweet.
real
It gets Sapp out of Tampa who we play 2x and is also in the NFL south. bad enough playing him once but 2x is suicidal. He still has some big hits in him and he takes cheap shots....
real